These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 25387856)

  • 1. Prediction of individual response to anticancer therapy: historical and future perspectives.
    Unger FT; Witte I; David KA
    Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
    Gerhards NM; Rottenberg S
    Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent applications of chemosensitivity tests for colorectal cancer treatment.
    Yoon YS; Kim JC
    World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data.
    Xu Y; Dong Q; Li F; Xu Y; Hu C; Wang J; Shang D; Zheng X; Yang H; Zhang C; Shao M; Meng M; Xiong Z; Li X; Zhang Y
    J Transl Med; 2019 Aug; 17(1):255. PubMed ID: 31387579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.
    Covell DG
    PLoS One; 2015; 10(7):e0127433. PubMed ID: 26132924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
    Lin F; Li Z; Hua Y; Lim YP
    Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.
    Kelleher MT; Fruhwirth G; Patel G; Ofo E; Festy F; Barber PR; Ameer-Beg SM; Vojnovic B; Gillett C; Coolen A; Kéri G; Ellis PA; Ng T
    Target Oncol; 2009 Sep; 4(3):235-52. PubMed ID: 19756916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
    Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine.
    Kim HS; Sung YJ; Paik S
    Yonsei Med J; 2015 Sep; 56(5):1186-98. PubMed ID: 26256959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis.
    Blom K; Nygren P; Larsson R; Andersson CR
    SLAS Technol; 2017 Jun; 22(3):306-314. PubMed ID: 28378608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer drug discovery using chemical genomics.
    Sehgal A
    Curr Med Chem; 2003 May; 10(9):749-55. PubMed ID: 12678778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement.
    Morgan MM; Johnson BP; Livingston MK; Schuler LA; Alarid ET; Sung KE; Beebe DJ
    Pharmacol Ther; 2016 Sep; 165():79-92. PubMed ID: 27218886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and use of biomarkers in oncology drug development.
    Floyd E; McShane TM
    Toxicol Pathol; 2004; 32 Suppl 1():106-15. PubMed ID: 15209410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of chemosensitivity testing.
    Blumenthal RD
    Methods Mol Med; 2005; 110():3-18. PubMed ID: 15901922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting cancer drug response by proteomic profiling.
    Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
    Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [OMICS and biomarkers of glial tumors].
    Idbaih A
    Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.